Intelligence · Clinical Pipeline

Neurology & CNS · Phase I

Neurology & CNS programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs: 142

Quick answer

Neurology & CNS Phase I programs: NovaPharmaNews indexes 142 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

300 mg [C14] CT1812

COGNITION THERAPEUTICS INC

Alzheimer Disease

phase 1 small molecule completed

1 trial
50mg Ezogabine/retigabine

GlaxoSmithKline

Epilepsy

phase 1 small molecule completed

1 trial
A Clinical Study to Assess the Safety, Tolerability of JNJ-63733657 and to evaluate how fast and to what extent JNJ-63733657 reaches the bloodstream and is absorbed, modified and removed from the body when administered as a Subcutaneous Infusion Using a Syringe Pump and as an Intravenous Infusion in Healthy Adult Participants

Janssen-Cilag International N.V.

Alzheimer's Disease (Healthy Participants)

phase 1 other active

1 trial
A First-in-Human Study to Evaluate the Safety and Tolerability of ALN-APP in Patients with EOAD

Alnylam Netherlands B.V.

Early-onset Alzheimer's disease (EOAD)

phase 1 other active

1 trial
A Multiple-Ascending-Dose Study of MK-1708 in Healthy Participants

Merck Sharp and Dohme

Amyotrophic lateral sclerosis and Alzheimer’s disease

phase 1 other active

1 trial
A PET Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants

Bristol-Myers Squibb Australia Pty Ltd

Neuropsychiatric indications and potentially other conditions

phase 1 other active

1 trial
A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or MG(Breakfree-2)

Celgene Europe Limited

Myasthenia gravis (MG), Progressive Multiple Sclerosis (PMS), Relapsing Multiple Sclerosis (RMS)

phase 1 other active

1 trial
A Phase 1, Open-Label Study to Investigate the TARP-ɣ8 Receptor Occupancy of RAP-219 Using a TARP-γ8 PET Tracer in Healthy Adult Participants

Rapport Therapeutics

Epilepsy

phase 1 other active

1 trial
A Phase 1, Randomized, Placebo-controlled Study with a Double-blind Period with Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients with Alzheimer’s Disease

Alnylam Netherlands B.V.

Alzheimer’s Disease

phase 1 other active

1 trial
A Phase I, open-label, non-randomized study to evaluate the absorption, distribution, metabolism and excretion and pharmacokinetics of DLX313 (minzasolmin) following a single oral dose of [14C]DLX313 in healthy male participants

Novartis Pharmaceuticals

Parkinson’s Disease

phase 1 other active

1 trial
A Randomized, Multiple-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 and the Relative Bioavailability at Steady-State of LY03010 versus XEPLION® in Patients with Schizophrenia

Lacuna Pharma Pty Ltd

Schizophrenia

phase 1 other active

1 trial
A SINGLE-ARM, OPEN-LABEL, PHASE I STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF OBE-CEL IN PARTICIPANTS WITH REFRACTORY PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS

Autolus GmbH

Refractory Progressive Multiple Sclerosis

phase 1 other active

1 trial
A Study to Assess Distribution, Binding, and Retention of the Monoclonal Antibody Trontinemab in the Brain of Healthy Participants and Patients with Alzheimer’s Disease

Hoffmann-La Roche

Alzheimer’s Disease (AD)

phase 1 other active

1 trial
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants with Early Alzheimer’s Disease

Denali Therapeutics

Early Alzheimer's Disease

phase 1 other active

1 trial
A Study to Investigate Single Ascending Doses of Ocrelizumab for Safety and Side Effects, How The Body Handles It Over A Period of Time, How The Body Notices and Reacts To It, And Its Effect On The Body When Given As A Subcutaneous Injection In Patients With Multiple Sclerosis

Hoffmann-La Roche

Multiple Sclerosis (MS)

phase 1 other active

1 trial
A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Ascending Intravenous Doses of Glofitamab, Administered after Ocrelizumab Pretreatment, in Patients with Multiple Sclerosis

Hoffmann-La Roche

Multiple Sclerosis (MS)

phase 1 other active

1 trial
A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of RO7121932 following Intravenous and Subcutaneous Administration in Participants with Multiple Sclerosis

Hoffmann-La Roche

Multiple Sclerosis (MS)

phase 1 other active

1 trial
A clinical trial to learn how an investigational drug (MP-101) affects on the laboratory signs of the disease when given to Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s Disease (AD) patients

Lacuna Pharma Pty Ltd

Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD)

phase 1 other active

1 trial
A positron emission tomography study of synaptic nerve cells proteins alpha-7 nicotinic acetylcholine receptors in brain of healthy volunteers and patients with mild cognitive impairment and Alzheimer´s disease.

The George Institute

Alzheimer´s disease

phase 1 other active

1 trial
A randomised, double-blind, placebo-controlled phase Ib trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of ACD856 in healthy participants

Lacuna Pharma Pty Ltd

Depression, Cognitive dysfunction, Alzheimer’s disease

phase 1 other active

1 trial
A study investigating the safety, absorption, and elimination of radioactively labeled RO7269162, a new compound that may potentially be used in the treatment of Alzheimer’s disease.

Hoffmann-La Roche

Healthy males volunteers

phase 1 other active

1 trial
A study to find out how healthy people tolerate a new drug called S221237.

The George Institute

Parkinson disease (PD)

phase 1 other active

1 trial
A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson’s disease.

Hoffmann-La Roche

Parkinson’s Disease

phase 1 other active

1 trial
ACTOS (Pioglitazone)

Takeda

Multiple Sclerosis, Relapsing-Remitting

phase 1 small molecule completed

1 trial
ACU193

Acumen Pharmaceuticals

Alzheimer Disease

phase 1 small molecule completed

1 trial
ALN-5288

Alnylam Netherlands B.V.

Alzheimer's Disease

phase 1 small molecule active

1 trial
ALN-APP

Alnylam Netherlands B.V.

Early-Onset Alzheimer Disease

phase 1 small molecule active

1 trial
ALN-SNCA

Regeneron UK Limited

Parkinsons Disease

phase 1 small molecule active

1 trial
APX005M treatment for recurrent or refractory primary malignant CNS tumor patients

Pyxis Oncology

Glioblastoma Multiforme

phase 1 mab active

1 trial
An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants with Schizophrenia

Lacuna Pharma Pty Ltd

Schizophrenia

phase 1 other active

1 trial
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Lamotrigine Dispersible Tablets BP 100 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Lamictal (Lamotrigine) Dispersible Tablets 100 mg, Manufactured by: Delpharm Poznaÿ – Poland & Registered and Imported by: GlaxoSmithKline Brasil Ltda, in healthy adult, human subjects under fasting condition.

Lacuna Pharma Pty Ltd

Bipolar disorder, Epilepsy

phase 1 other active

1 trial
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Brivaracetam Tablets Ph. Eur. 100 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Briviact (brivaracetam) 100 mg film-coated tablets, Marketing Authorisation Holder: UCB Pharma S.A., Allée de la Recherche 60, B-1070 Bruxelles, Belgium; Manufactured by UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l’Alleud, Belgium, in healthy adult, human subjects und

Lacuna Pharma Pty Ltd

Epilepsy

phase 1 other active

1 trial
BIIB094

IONIS PHARMACEUTICALS INC

Parkinson's Disease

phase 1 small molecule completed

1 trial
BIS-001 ER

SUPERNUS PHARMACEUTICALS, INC.

Epilepsy, Complex Partial

phase 1 small molecule completed

1 trial
BXCL501 80 Micrograms

BioXcel Therapeutics

Schizophrenia

phase 1 small molecule active

1 trial
Bioequivalence of Cladribine 10 mg from two different products

Lacuna Pharma Pty Ltd

No therapeutic indication in the current trial with healthy volunteers. The intended indication is for treatment of adult patients with highly active relapsing multiple sclerosis (MS).

phase 1 other active

1 trial
Bioequivalence study 1 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers

Orion Laboratories Pty.

Parkinson disease

phase 1 other active

1 trial
Bioequivalence study 2 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers

Orion Laboratories Pty.

Parkinson desease

phase 1 other active

1 trial
CERE-110: Adeno-Associated Virus Delivery of NGF

SANGAMO THERAPEUTICS, INC

Alzheimer's Disease

phase 1 gene therapy completed

1 trial
CERE-120: AAV2-NTN

SANGAMO THERAPEUTICS, INC

Parkinson's Disease

phase 1 gene therapy completed

1 trial
CNCT19 cell injection

Juventas Cell Therapy

Neurological Autoimmune Diseases

phase 1 mab active

1 trial
Carbidopa

United Therapeutics Europe Ltd

Multiple Sclerosis

phase 1 small molecule completed

1 trial
Characterization of Immune Response in Participants from a Posdinemab Study

Janssen-Cilag International N.V.

Early Alzheimer's disease

phase 1 other active

1 trial
Citalopram

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Depression

phase 1 small molecule active

1 trial
DIPHENHYDRAMINE, METHYLPREDNISOLONE, PARACETAMOL, ublituximab, Ublituximab, ublituximab, CETIRIZINE, DEXAMETHASONE

TG THERAPEUTICS, INC.

Relapsing multiple sclerosis, Myasthenia Gravis

phase 1 small molecule active

1 trial
DNL201

Denali Therapeutics

Parkinson Disease

phase 1 small molecule completed

1 trial
DNL628

Denali Therapeutics

Alzheimer Disease, Early Onset

phase 1 small molecule active

1 trial
DNL747

Denali Therapeutics

Alzheimer Disease

phase 1 small molecule completed

1 trial

Frequently asked questions

How many neurology & cns Phase I programs exist?

142 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Quick answer

Top sponsors

300 mg [C14] CT1812

50mg Ezogabine/retigabine

A First-in-Human Study to Evaluate the Safety and Tolerability of ALN-APP in Patients with EOAD

A Multiple-Ascending-Dose Study of MK-1708 in Healthy Participants

A PET Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants

A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or MG(Breakfree-2)

A Phase 1, Open-Label Study to Investigate the TARP-ɣ8 Receptor Occupancy of RAP-219 Using a TARP-γ8 PET Tracer in Healthy Adult Participants

A Phase 1, Randomized, Placebo-controlled Study with a Double-blind Period with Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients with Alzheimer’s Disease

A Phase I, open-label, non-randomized study to evaluate the absorption, distribution, metabolism and excretion and pharmacokinetics of DLX313 (minzasolmin) following a single oral dose of [14C]DLX313 in healthy male participants

A Randomized, Multiple-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 and the Relative Bioavailability at Steady-State of LY03010 versus XEPLION® in Patients with Schizophrenia

A SINGLE-ARM, OPEN-LABEL, PHASE I STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF OBE-CEL IN PARTICIPANTS WITH REFRACTORY PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS

A Study to Assess Distribution, Binding, and Retention of the Monoclonal Antibody Trontinemab in the Brain of Healthy Participants and Patients with Alzheimer’s Disease

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants with Early Alzheimer’s Disease

A Study to Investigate Single Ascending Doses of Ocrelizumab for Safety and Side Effects, How The Body Handles It Over A Period of Time, How The Body Notices and Reacts To It, And Its Effect On The Body When Given As A Subcutaneous Injection In Patients With Multiple Sclerosis

A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Ascending Intravenous Doses of Glofitamab, Administered after Ocrelizumab Pretreatment, in Patients with Multiple Sclerosis

A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of RO7121932 following Intravenous and Subcutaneous Administration in Participants with Multiple Sclerosis

A clinical trial to learn how an investigational drug (MP-101) affects on the laboratory signs of the disease when given to Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s Disease (AD) patients

A positron emission tomography study of synaptic nerve cells proteins alpha-7 nicotinic acetylcholine receptors in brain of healthy volunteers and patients with mild cognitive impairment and Alzheimer´s disease.

A randomised, double-blind, placebo-controlled phase Ib trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of ACD856 in healthy participants

A study investigating the safety, absorption, and elimination of radioactively labeled RO7269162, a new compound that may potentially be used in the treatment of Alzheimer’s disease.

A study to find out how healthy people tolerate a new drug called S221237.

A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson’s disease.

ACTOS (Pioglitazone)

ACU193

ALN-5288

ALN-APP

ALN-SNCA

APX005M treatment for recurrent or refractory primary malignant CNS tumor patients

An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants with Schizophrenia

BIIB094

BIS-001 ER

BXCL501 80 Micrograms

Bioequivalence of Cladribine 10 mg from two different products

Bioequivalence study 1 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers

Bioequivalence study 2 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers

CERE-110: Adeno-Associated Virus Delivery of NGF

CERE-120: AAV2-NTN

CNCT19 cell injection

Carbidopa

Characterization of Immune Response in Participants from a Posdinemab Study

Citalopram

DIPHENHYDRAMINE, METHYLPREDNISOLONE, PARACETAMOL, ublituximab, Ublituximab, ublituximab, CETIRIZINE, DEXAMETHASONE

DNL201

DNL628

DNL747

Frequently asked questions

Stay Ahead in Pharma